AB InBev PureDraught™ Keg System Wins World Beverage Innovation Award
18.11.2019 17:20:00 EET | Business Wire | Press release
AB InBev and its Global Innovation and Technology Center (GITEC) announced that PureDraught™, a revolutionary one-way polymer keg system, won a World Beverage Innovation Award for “Best Manufacturing/Processing Innovation.” The honor was awarded at the BrauBeviale 2019 trade fair in Nuremberg, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191118005495/en/
PureDraught™ keeps beer fresher up to four times longer than a traditional steel keg and reduces the carbon footprint of shipping beer -- all while offering more versatility and variety for bar and restaurant owners. (Photo: Business Wire)
PureDraught™ keeps beer fresher up to four times longer than a traditional steel keg and reduces the carbon footprint of shipping beer -- all while offering more versatility and variety for bar and restaurant owners.
Using a custom-molded, double-walled, bottle-in-bottle polymer keg, PureDraught allows air or gas to be fed into the outer bottle, which keeps its shape and pushes the beer out of the inner bottle. This innovation prevents any air or dispense gas from touching the beer, allowing the beer to remain fresh for 30 days after being tapped instead of just a week.
In addition, PureDraught comes in 6L, 12L and 18L sizes rather than the standard 30L or larger steel keg size, allowing for more flexibility and less wasted product by bar and restaurant owners. The kegs can be stored and dispensed from upright or on their side on a shelf, making them more versatile.
“We are honored that our research and technological innovation for PureDraught has been recognized by the prestigious World Beverage Innovation Awards,” said Rodrigo Sozo, Vice President of AB InBev GITEC. “This is a validation of the hard work and passion of our team as they set out to develop a transformational innovation for draught beer, including superior quality, less carbon footprint and more variety of beers on tap. We are also excited about how the technology platform creates new consumer experiences for all types of occasions of draught beer consumption.”
There are no additional costs for a bar to use the PureDraught system or the beer in the one-way kegs, and in most markets, the system’s custom keg coupler is provided and connected to a bar’s existing beer and gas lines by AB InBev free of charge.
Currently, PureDraught is in use with AB InBev brands in more than eight countries, including the U.S., Mexico, Brazil, China, Italy, Japan and South Korea as well as additional areas of Europe and Africa, providing the best pour of brands like Stella Artois. For more information, including how to convert your establishment to PureDraught, visit https://puredraught.com/.
About AB InBev GITEC
The Global Innovation and Technology Center (GITEC) at AB InBev is the hub of innovation for the company, working across teams and the company’s more than 500 brands to develop new products, processes and technologies. Driven by a team of more than 120 passionate R&D talents from more than 20 countries, GITEC works to revolutionize packaging, make the brewing process more efficient and sustainable, create breakthroughs in how our beers are delivered and dispensed, and to offer new tasting and consumer experiences.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191118005495/en/
Contact information
Media Contact:
Shawn Malayter
Greenhouse Partners
872-267-2636
smalayter@greenhousepartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom